EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters

Ming-Shu Hsieh, Chia-Wei Hsu, Hung-Chun Liao, Chang-Ling Lin, Chen-Yi Chiang, Mei-Yu Chen, Shih-Jen Liu, Ching-Len Liao, Hsin-Wei Chen iD

Journal of Virology · 2024

DOI: 10.1128/jvi.01546-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Ming-Shu Hsieh und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan. Hauptthemen laut MEDLINE: Bacterial Proteins, COVID-19, COVID-19 Vaccines, Immunity, Mucosal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes (NHRI), National Science and Technology Council (NSTC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccine-induced mucosal immunity and broad protective capacity against various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remain inadequate. Formyl peptide receptor-like 1 inhibitory protein (FLIPr), produced by Staphylococcus aureus , can bind to various Fcγ receptor subclasses. Recombinant lipidated FLIPr (rLF) was previously found to be an effective adjuvant. In this study, we developed a vaccine candidate, the recombinant Delta SARS-CoV-2 spike (rDS)-FLIPr fusion protein (rDS-F), which employs the property of FLIPr binding to various Fcγ receptors. Our study shows that rDS-F plus rLF promotes rDS capture by dendritic cells. Intranasal vaccination of mice with rDS-F plus rLF increases persistent systemic and mucosal antibody responses and CD4/CD8 T-cell responses. Importantly, antibodies induced by rDS-F plus rLF vaccination neutralize Delta, Wuhan, Alpha, Beta, and Omicron strains. Additionally, rDS-F plus rLF provides protective effects against various SARS-CoV-2 variants in hamsters by reducing inflammation and viral loads in the lung. Therefore, rDS-F plus rLF is a potential vaccine candidate to induce broad protective responses against various SARS-CoV-2 variants. IMPORTANCE Mucosal immunity is vital for combating pathogens, especially in the context of respiratory diseases like COVID-19. Despite this, most approved vaccines are administered via injection, providing systemic but limited mucosal protection. Developing vaccines that stimulate both mucosal and systemic immunity to address future coronavirus mutations is a growing trend. However, eliciting strong mucosal immune responses without adjuvants remains a challenge. In our study, we have demonstrated that using a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-formyl peptide receptor-like 1 inhibitory protein (FLIPr) fusion protein as an antigen, in combination with recombinant lipidated FLIPr as an effective adjuvant, induced simultaneous systemic and mucosal immune responses through intranasal immunization in mice and hamster models. This approach offered protection against various SARS-CoV-2 strains, making it a promising vaccine candidate for broad protection. This finding is pivotal for future broad-spectrum vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bacterial ProteinsCOVID-19COVID-19 VaccinesImmunity, MucosalLipidsRecombinant Fusion ProteinsSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsCricetinaeMiceAdjuvants, ImmunologicAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDendritic CellsDisease Models, AnimalReceptors, IgGStaphylococcus aureusVaccine DevelopmentViral Load

Stichwörter der Autor:innen

FLIPrSARS-CoV-2T-cell responsemucosal immunityneutralizing antibodiesvaccine developmentvariants

Substanzen

Adjuvants, ImmunologicAntibodies, ViralBacterial ProteinsCOVID-19 VaccinesFPRL1 inhibitory protein, S aureusLipidsReceptors, IgGRecombinant Fusion ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan.
  • Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
  • Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

ORCID-Profile: Hsin-Wei Chen

Förderung

  • National Health Research Institutes (NHRI)
  • National Science and Technology Council (NSTC)

Zitieren

APA

Hsieh, M. S., Hsu, C. W., Liao, H. C., Lin, C. L., Chiang, C. Y., Chen, M. Y., Liu, S. J., Liao, C. L., & Chen, H. W. (2024). SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters. Journal of Virology. https://doi.org/10.1128/jvi.01546-23

Vancouver

Hsieh MS, Hsu CW, Liao HC, Lin CL, Chiang CY, Chen MY, et al. SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters. Journal of Virology. 2024. doi:10.1128/jvi.01546-23

BibTeX
@article{Hsieh2024,
  author = {Hsieh, Ming-Shu and Hsu, Chia-Wei and Liao, Hung-Chun and Lin, Chang-Ling and Chiang, Chen-Yi and Chen, Mei-Yu and Liu, Shih-Jen and Liao, Ching-Len and Chen, Hsin-Wei},
  title = {SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.01546-23}
}
Kostenlos starten →